TriSalus Life Sciences (NASDAQ:TLSI) Trading 1.3% Higher – Still a Buy?

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) shares traded up 1.3% during mid-day trading on Monday . The stock traded as high as $3.33 and last traded at $3.21. 237,997 shares were traded during trading, a decline of 70% from the average session volume of 796,421 shares. The stock had previously closed at $3.17.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Lake Street Capital reduced their price objective on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Weiss Ratings lowered shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Canaccord Genuity Group dropped their price target on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, March 6th. Finally, Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $7.50.

TriSalus Life Sciences Stock Up 6.3%

The firm’s 50-day moving average price is $3.89 and its 200-day moving average price is $4.98. The company has a quick ratio of 5.46, a current ratio of 5.78 and a debt-to-equity ratio of 2.58.

Insider Transactions at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela acquired 39,682 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $2.59 per share, with a total value of $102,776.38. Following the completion of the transaction, the chief executive officer directly owned 1,065,215 shares of the company’s stock, valued at approximately $2,758,906.85. The trade was a 3.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mats Wahlstrom acquired 60,000 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was acquired at an average cost of $2.53 per share, with a total value of $151,800.00. Following the transaction, the director directly owned 147,555 shares of the company’s stock, valued at approximately $373,314.15. This represents a 68.53% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 719,682 shares of company stock valued at $1,804,176 and sold 22,043 shares valued at $86,367. Company insiders own 16.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TLSI. First Light Asset Management LLC purchased a new position in shares of TriSalus Life Sciences in the first quarter valued at $20,267,000. Nantahala Capital Management LLC purchased a new position in shares of TriSalus Life Sciences in the second quarter valued at $10,900,000. Wasatch Advisors LP purchased a new position in shares of TriSalus Life Sciences in the first quarter valued at $5,752,000. Vanguard Group Inc. boosted its stake in shares of TriSalus Life Sciences by 42.4% in the third quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after purchasing an additional 345,186 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC boosted its stake in shares of TriSalus Life Sciences by 32.1% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after purchasing an additional 265,618 shares during the period. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.